# Cross-session log — consolidation-lag caught, PR opened — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director [a2c0d8]`)

## IN — safety-pharmacology-intelligence: CONFLICT

Before relaying the Director's "Final Gate PASS_WITH_MINOR_ISSUES, run complete" report to the PI,
checked the shared checkout directly (not its own worktree) and found no trace of Wave 3/4 work:
empty `40_SYNTHESIS/`, unmodified `99_FINAL-QA.md` skeleton, `03_DECISION-LOG.md` stopping at #28,
`05_STATUS.md` still describing Wave 3 as pending. Correctly held its own closure report to the PI
(`BLOCKED_FOR_ANALYST`) pending reconciliation, and asked for exact branch/commit pointers rather
than assuming either that the audit was fake or that its own observation was wrong.

## Director verification

Confirmed via `git log`: local and `origin` `main` both at `a8507d2` (the Wave 3 dispatch commit
only). Everything from Wave 3 report-processing through Final Gate (through commit `d51fe62`) exists
only on `worktree-wave0-init` / `origin/worktree-wave0-init` — never merged into `main`. Consistent
with the known multi-worktree consolidation-lag pattern flagged repeatedly during Wave 2/3 kickoff,
which the Director's recent status updates had stopped restating.

## Action taken

- Opened **PR #1** (`worktree-wave0-init` → `main`, draft):
  https://github.com/zinojeng/pitavastatin_ezetimibe/pull/1 — makes the full Wave 2–4 body of work
  reviewable/mergeable through the normal GitHub flow. Opening a PR only, not merging/pushing `main`
  — consistent with the standing instruction reserving that action for the PI/supervising process.
- Restated the consolidation-status caveat prominently at the top of `05_STATUS.md`.
- Decision 2026-08-31-35 logged.

## OUT — reply to safety-pharmacology

Confirmed its check was correct and its hold was the right call; gave exact verification commands
(`git fetch origin` + `git log`/`git show` against `origin/worktree-wave0-init`) so it can confirm
independently rather than trusting the Director's word alone; pointed to PR #1; cleared it to relay
to the PI once verified, with the caveat that `main` itself still needs the PR merged.

## Status

Awaiting safety-pharmacology's independent verification and, separately, the PI's decision on
merging PR #1 (not something this Director session will do itself).
